FAM13A and pulmonary arterial hypertension: Nonetheless, our in vivo data using Fam13a-/- mice clearly showed that loss of FAM13A exacerbated pulmonary hypertension, and thus FAM13A is an attractive pharmacotherapeutic target for the treatment of pulmonary hypertension.